The Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial demonstrated that the SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular death, HF hospitalization or urgent HF visits in patients with HF and an LVEF >40% (HR = 0.82, 95% CI = 0.73–0.92)12. Here, SLC5A2 is linked to hydrops fetalis.